Exelixis, Inc.

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
30161Q104
SEDOL
BD6TF28
CIK
0000939767
www.exelixis.com
LEI:
©
FIGI: BBG000BQ4WF8
EXEL
Exelixis, Inc.
GICS: - · Sektor: Healthcare · Sub-Sektor: Biotechnology
AI
PROFILER
NAME
Exelixis, Inc.
ISIN
US30161Q1040
TICKER
EXEL
MIC
XNAS
REUTERS
EXEL.OQ
BLOOMBERG
EXEL US
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
GIF DE 728x90
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Mo., 06.01.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. PT / 8:15 p.m. PT. To access the webcast link, log onto www.exelixis.com and proceed t...
weiterlesen
Exelixis
Research & Analysen Termsheet Terminal
Permalink
Mi., 27.11.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in December: Piper Sandler 36th Annual Healthcare Conference: Exelixis is scheduled to present at 8:30 a.m. ET / 5:30 a.m. PT on Tuesday, December 3 in New York City. Citi 2024 Global Healthcare Confe...
weiterlesen
Exelixis
Research & Analysen Termsheet Terminal
Permalink
Di., 26.11.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will b...
weiterlesen
Exelixis
Research & Analysen Termsheet Terminal
Permalink
Do., 07.11.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheim’s Inaugural Healthcare Innovation Conference: Exelixis is scheduled to present at 9:00 a.m. ET / 6:00 a.m. PT on Tuesday, November 12 in Boston. Stifel 2024 Healthcare Conference...
weiterlesen
Exelixis
Research & Analysen Termsheet Terminal
Permalink
Di., 29.10.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline development milestones. “The favorable ruling on our cabozantinib intellectual property estate and recentl...
weiterlesen
Exelixis
Research & Analysen Termsheet Terminal
Permalink
Di., 15.10.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2024 financial results will be released on Tuesday, October 29, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available...
weiterlesen
Exelixis
Research & Analysen Termsheet Terminal
Permalink
Di., 15.10.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. District Court for the District of Delaware ruled in Exelixis’ favor, rejecting MSN’s challenge to three Orange Book-listed patents related to cabozantinib...
weiterlesen
Exelixis
Research & Analysen Termsheet Terminal
Permalink
Mo., 14.10.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the companies have entered into a clinical development collaboration to evaluate the combination of Exelixis’ investigational tyrosine kinase inhibitor (TKI) zanzalintinib with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrol...
weiterlesen
Exelixis
Research & Analysen Termsheet Terminal
Permalink
Mo., 16.09.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced updated and final data from CABINET, a phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) versus placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort with advanced pancreatic neuroendocrine tumors (pNET) and one cohort with advanced extra-pancreatic NET (...
weiterlesen
Exelixis
Research & Analysen Termsheet Terminal
Permalink
So., 15.09.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced detailed final overall survival (OS) results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab (Tecentriq®) compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measu...
weiterlesen
Exelixis
Research & Analysen Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S